Oligonucleotides Targeted Against a Junction Oncogene Are Made Efficient by Nanotechnologies View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2003-10

AUTHORS

Andrei Maksimenko, Claude Malvy, Gregory Lambert, Jean-Rémy Bertrand, Elias Fattal, Jean Maccario, Patrick Couvreur

ABSTRACT

PURPOSE: Antisense oligonucleotides (AON) against junction EWS-Fli-1 oncogene (which is responsible for the Ewing Sarcoma) are particularly interesting for targeting chromosomal translocations that are only found in tumor cells. However, these AON have proved in the past to be ineffective in vivo because of their susceptibility to degradation and their poor intracellular penetration. The aim of this study was to improve the delivery of these molecules through the use of nanotechnologies. METHOD: Two different AONs, and their controls, both targeted against the junction area of the fusion gene EWS-Fli-1 were used. Nanocapsules were employed to deliver a phosphorothioate AON and its control. The nanospheres were used to deliver a chimeric phosphorothioate, phosphodiester AON, with 5 additional bases in 5' which allow this AON to be structured with a loop. These formulations were injected intratumorally to nude mice bearing the experimental EWS-Fli-1 tumor. The tumour volume was estimated during the experiments by two perpendicular measurements length (a) and width (b) of the tumour and was calculated as ab(2)/2. Northern blot analysis was also performed after removing the tumors 24 h after the treatment with a single dose of AON either free or associated with nanotechnologies. RESULTS: This study shows for the first time that AON against EWS-Fli-1 oncogene may inhibit with high specificity the growth of an EWS-Fli-1 dependent tumor grafted to nude mice provided they are delivered by nanocapsules or nanospheres. In this experience, the antisense effect was confirmed by the specific down regulation of EWS-Fli-1 mRNA. CONCLUSION: Thus, both nanocapsules and nanospheres may be considered as promising systems for AON delivery in vivo. More... »

PAGES

1565-1567

Identifiers

URI

http://scigraph.springernature.com/pub.10.1023/a:1026122914852

DOI

http://dx.doi.org/10.1023/a:1026122914852

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1005136437

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/14620508


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blotting, Northern", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Capsules", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Delivery Systems", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gene Transfer Techniques", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mice", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mice, Nude", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nanotechnology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oligonucleotides, Antisense", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oncogene Proteins, Fusion", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Particle Size", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proto-Oncogene Protein c-fli-1", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "RNA-Binding Protein EWS", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sarcoma, Ewing", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Transcription Factors", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Onxeo (France)", 
          "id": "https://www.grid.ac/institutes/grid.432920.e", 
          "name": [
            "Institut Gustave Roussy, CNRS UMR 1582, 39 rue Camille Desmoulins, 94805, Villejuif cedex, France", 
            "BioAlliance Pharma, 59, Boulevard du G\u00e9n\u00e9ral Martial Valin, 75015, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Maksimenko", 
        "givenName": "Andrei", 
        "id": "sg:person.01340771606.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340771606.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Gustave Roussy", 
          "id": "https://www.grid.ac/institutes/grid.14925.3b", 
          "name": [
            "Institut Gustave Roussy, CNRS UMR 1582, 39 rue Camille Desmoulins, 94805, Villejuif cedex, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Malvy", 
        "givenName": "Claude", 
        "id": "sg:person.01037610656.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01037610656.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Novagali SAS, 4 rue Pierre Fontaine, 91000, Evry, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lambert", 
        "givenName": "Gregory", 
        "id": "sg:person.01266265435.77", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01266265435.77"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Gustave Roussy", 
          "id": "https://www.grid.ac/institutes/grid.14925.3b", 
          "name": [
            "Institut Gustave Roussy, CNRS UMR 1582, 39 rue Camille Desmoulins, 94805, Villejuif cedex, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bertrand", 
        "givenName": "Jean-R\u00e9my", 
        "id": "sg:person.010236660502.77", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010236660502.77"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Gustave Roussy", 
          "id": "https://www.grid.ac/institutes/grid.14925.3b", 
          "name": [
            "Institut Gustave Roussy, CNRS UMR 1582, 39 rue Camille Desmoulins, 94805, Villejuif cedex, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fattal", 
        "givenName": "Elias", 
        "id": "sg:person.01146450602.87", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01146450602.87"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Paris-Sud", 
          "id": "https://www.grid.ac/institutes/grid.5842.b", 
          "name": [
            "INSERM, Universit\u00e9 Paris-Sud, 94805, Villejuif, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Maccario", 
        "givenName": "Jean", 
        "id": "sg:person.0761332540.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0761332540.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Facult\u00e9 de Pharmacie, Chatenay-, CNRS UMR 8612, Malabry, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Couvreur", 
        "givenName": "Patrick", 
        "id": "sg:person.0760312615.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0760312615.72"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1172/jci119152", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014854312"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1006/bbrc.2000.3963", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017328614"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1007582332491", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032461777", 
          "https://doi.org/10.1023/a:1007582332491"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1015871809313", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035402570", 
          "https://doi.org/10.1023/a:1015871809313"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/07328319908044865", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041217538"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2003-10", 
    "datePublishedReg": "2003-10-01", 
    "description": "PURPOSE: Antisense oligonucleotides (AON) against junction EWS-Fli-1 oncogene (which is responsible for the Ewing Sarcoma) are particularly interesting for targeting chromosomal translocations that are only found in tumor cells. However, these AON have proved in the past to be ineffective in vivo because of their susceptibility to degradation and their poor intracellular penetration. The aim of this study was to improve the delivery of these molecules through the use of nanotechnologies.\nMETHOD: Two different AONs, and their controls, both targeted against the junction area of the fusion gene EWS-Fli-1 were used. Nanocapsules were employed to deliver a phosphorothioate AON and its control. The nanospheres were used to deliver a chimeric phosphorothioate, phosphodiester AON, with 5 additional bases in 5' which allow this AON to be structured with a loop. These formulations were injected intratumorally to nude mice bearing the experimental EWS-Fli-1 tumor. The tumour volume was estimated during the experiments by two perpendicular measurements length (a) and width (b) of the tumour and was calculated as ab(2)/2. Northern blot analysis was also performed after removing the tumors 24 h after the treatment with a single dose of AON either free or associated with nanotechnologies.\nRESULTS: This study shows for the first time that AON against EWS-Fli-1 oncogene may inhibit with high specificity the growth of an EWS-Fli-1 dependent tumor grafted to nude mice provided they are delivered by nanocapsules or nanospheres. In this experience, the antisense effect was confirmed by the specific down regulation of EWS-Fli-1 mRNA.\nCONCLUSION: Thus, both nanocapsules and nanospheres may be considered as promising systems for AON delivery in vivo.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1023/a:1026122914852", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094644", 
        "issn": [
          "0724-8741", 
          "1573-904X"
        ], 
        "name": "Pharmaceutical Research", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "10", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "20"
      }
    ], 
    "name": "Oligonucleotides Targeted Against a Junction Oncogene Are Made Efficient by Nanotechnologies", 
    "pagination": "1565-1567", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "1878dcf15c687a6ce3c8c3f46eba86396f711d57782b7c06475f161adc935f99"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "14620508"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8406521"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1023/a:1026122914852"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1005136437"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1023/a:1026122914852", 
      "https://app.dimensions.ai/details/publication/pub.1005136437"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T13:13", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8659_00000503.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1023%2FA%3A1026122914852"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1023/a:1026122914852'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1023/a:1026122914852'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1023/a:1026122914852'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1023/a:1026122914852'


 

This table displays all metadata directly associated to this object as RDF triples.

207 TRIPLES      21 PREDICATES      51 URIs      38 LITERALS      26 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1023/a:1026122914852 schema:about N1147ae63b85d4cc5a62654f9e3a648f9
2 N19f5c783b0ed4e789637ceb151a03890
3 N31254110ecf84973bd00dcee04b3dd49
4 N53c3453579c942718b66cbb04a8ac100
5 N59e66b295cb84c62a570931b0b1cfecf
6 N5f06f4a5913b4c7796c862d2cf553dc6
7 N67163c64035a492f963bfbe32544a49b
8 Na152226ccdcf444093a0fbb04237b8a6
9 Na35581ee371f4c8cb73fc889ce4af735
10 Na8d399c7eb4047c6b44c6711f57c886c
11 Nb37290b84b3549f78f52fb81f3a97252
12 Nb3b9a5e67ba14ac08034c684328535f5
13 Nb5466196732f4df2ae7e493c55a486e0
14 Nb75c62d3babf473d953293b1a11887ed
15 Nbb57faf4b9d84daba94585f4b9fbc21e
16 Ne0be104d8dee4ee3bb87398e667d6a74
17 Nf9e8e061759e42dcaee5202b25a528d2
18 anzsrc-for:11
19 anzsrc-for:1112
20 schema:author N8af8f27a16374d19ae36be42d89fe18f
21 schema:citation sg:pub.10.1023/a:1007582332491
22 sg:pub.10.1023/a:1015871809313
23 https://doi.org/10.1006/bbrc.2000.3963
24 https://doi.org/10.1080/07328319908044865
25 https://doi.org/10.1172/jci119152
26 schema:datePublished 2003-10
27 schema:datePublishedReg 2003-10-01
28 schema:description PURPOSE: Antisense oligonucleotides (AON) against junction EWS-Fli-1 oncogene (which is responsible for the Ewing Sarcoma) are particularly interesting for targeting chromosomal translocations that are only found in tumor cells. However, these AON have proved in the past to be ineffective in vivo because of their susceptibility to degradation and their poor intracellular penetration. The aim of this study was to improve the delivery of these molecules through the use of nanotechnologies. METHOD: Two different AONs, and their controls, both targeted against the junction area of the fusion gene EWS-Fli-1 were used. Nanocapsules were employed to deliver a phosphorothioate AON and its control. The nanospheres were used to deliver a chimeric phosphorothioate, phosphodiester AON, with 5 additional bases in 5' which allow this AON to be structured with a loop. These formulations were injected intratumorally to nude mice bearing the experimental EWS-Fli-1 tumor. The tumour volume was estimated during the experiments by two perpendicular measurements length (a) and width (b) of the tumour and was calculated as ab(2)/2. Northern blot analysis was also performed after removing the tumors 24 h after the treatment with a single dose of AON either free or associated with nanotechnologies. RESULTS: This study shows for the first time that AON against EWS-Fli-1 oncogene may inhibit with high specificity the growth of an EWS-Fli-1 dependent tumor grafted to nude mice provided they are delivered by nanocapsules or nanospheres. In this experience, the antisense effect was confirmed by the specific down regulation of EWS-Fli-1 mRNA. CONCLUSION: Thus, both nanocapsules and nanospheres may be considered as promising systems for AON delivery in vivo.
29 schema:genre research_article
30 schema:inLanguage en
31 schema:isAccessibleForFree false
32 schema:isPartOf N5ce67cf4cae74167af2ddb2774835e2d
33 N8df922c6d63f418b968ee4221cd04035
34 sg:journal.1094644
35 schema:name Oligonucleotides Targeted Against a Junction Oncogene Are Made Efficient by Nanotechnologies
36 schema:pagination 1565-1567
37 schema:productId N3410c6fe28434e5ba34bb565ef9a19de
38 N76a70457981f4e39b5b579a6d1329afe
39 N77cff414a49c42168fbc1745d823d088
40 Nd78263a3c469400081b1634bfa892127
41 Nec8cb6d3146841c89a9fac37e3ac40c3
42 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005136437
43 https://doi.org/10.1023/a:1026122914852
44 schema:sdDatePublished 2019-04-10T13:13
45 schema:sdLicense https://scigraph.springernature.com/explorer/license/
46 schema:sdPublisher N1fc1cca6787d4f4cbbf382392e0bae5f
47 schema:url http://link.springer.com/10.1023%2FA%3A1026122914852
48 sgo:license sg:explorer/license/
49 sgo:sdDataset articles
50 rdf:type schema:ScholarlyArticle
51 N0274774ed6e944d4a033185c57b5d1ef rdf:first sg:person.01146450602.87
52 rdf:rest N34099a1205b144e7858a6fcfe31fa3fe
53 N1147ae63b85d4cc5a62654f9e3a648f9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
54 schema:name RNA-Binding Protein EWS
55 rdf:type schema:DefinedTerm
56 N19f5c783b0ed4e789637ceb151a03890 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
57 schema:name Animals
58 rdf:type schema:DefinedTerm
59 N1fc1cca6787d4f4cbbf382392e0bae5f schema:name Springer Nature - SN SciGraph project
60 rdf:type schema:Organization
61 N31254110ecf84973bd00dcee04b3dd49 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
62 schema:name Oncogene Proteins, Fusion
63 rdf:type schema:DefinedTerm
64 N34099a1205b144e7858a6fcfe31fa3fe rdf:first sg:person.0761332540.51
65 rdf:rest N7e6eb4e425054c28970776d7b9f0cf37
66 N3410c6fe28434e5ba34bb565ef9a19de schema:name doi
67 schema:value 10.1023/a:1026122914852
68 rdf:type schema:PropertyValue
69 N3a16a4e22b6143ffbe7da6763232001b rdf:first sg:person.010236660502.77
70 rdf:rest N0274774ed6e944d4a033185c57b5d1ef
71 N4051a21ee1b54edf98fedce94d1a0729 rdf:first sg:person.01037610656.22
72 rdf:rest N680dd4175b834450a0fb5c5c477cea19
73 N53c3453579c942718b66cbb04a8ac100 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
74 schema:name Gene Transfer Techniques
75 rdf:type schema:DefinedTerm
76 N544fe22ffad843a8b510a8431cde39c3 schema:name Novagali SAS, 4 rue Pierre Fontaine, 91000, Evry, France
77 rdf:type schema:Organization
78 N59e66b295cb84c62a570931b0b1cfecf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
79 schema:name Capsules
80 rdf:type schema:DefinedTerm
81 N5ce67cf4cae74167af2ddb2774835e2d schema:issueNumber 10
82 rdf:type schema:PublicationIssue
83 N5f06f4a5913b4c7796c862d2cf553dc6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Particle Size
85 rdf:type schema:DefinedTerm
86 N5f3a7c8e6439498f843c7abc0eb97ddd schema:name Faculté de Pharmacie, Chatenay-, CNRS UMR 8612, Malabry, France
87 rdf:type schema:Organization
88 N67163c64035a492f963bfbe32544a49b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Nanotechnology
90 rdf:type schema:DefinedTerm
91 N680dd4175b834450a0fb5c5c477cea19 rdf:first sg:person.01266265435.77
92 rdf:rest N3a16a4e22b6143ffbe7da6763232001b
93 N76a70457981f4e39b5b579a6d1329afe schema:name pubmed_id
94 schema:value 14620508
95 rdf:type schema:PropertyValue
96 N77cff414a49c42168fbc1745d823d088 schema:name readcube_id
97 schema:value 1878dcf15c687a6ce3c8c3f46eba86396f711d57782b7c06475f161adc935f99
98 rdf:type schema:PropertyValue
99 N7e6eb4e425054c28970776d7b9f0cf37 rdf:first sg:person.0760312615.72
100 rdf:rest rdf:nil
101 N8af8f27a16374d19ae36be42d89fe18f rdf:first sg:person.01340771606.27
102 rdf:rest N4051a21ee1b54edf98fedce94d1a0729
103 N8df922c6d63f418b968ee4221cd04035 schema:volumeNumber 20
104 rdf:type schema:PublicationVolume
105 Na152226ccdcf444093a0fbb04237b8a6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Bone Neoplasms
107 rdf:type schema:DefinedTerm
108 Na35581ee371f4c8cb73fc889ce4af735 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Oligonucleotides, Antisense
110 rdf:type schema:DefinedTerm
111 Na8d399c7eb4047c6b44c6711f57c886c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Mice, Nude
113 rdf:type schema:DefinedTerm
114 Nb37290b84b3549f78f52fb81f3a97252 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Sarcoma, Ewing
116 rdf:type schema:DefinedTerm
117 Nb3b9a5e67ba14ac08034c684328535f5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Drug Delivery Systems
119 rdf:type schema:DefinedTerm
120 Nb5466196732f4df2ae7e493c55a486e0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Blotting, Northern
122 rdf:type schema:DefinedTerm
123 Nb75c62d3babf473d953293b1a11887ed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Proto-Oncogene Protein c-fli-1
125 rdf:type schema:DefinedTerm
126 Nbb57faf4b9d84daba94585f4b9fbc21e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Antineoplastic Agents
128 rdf:type schema:DefinedTerm
129 Nd78263a3c469400081b1634bfa892127 schema:name dimensions_id
130 schema:value pub.1005136437
131 rdf:type schema:PropertyValue
132 Ne0be104d8dee4ee3bb87398e667d6a74 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Transcription Factors
134 rdf:type schema:DefinedTerm
135 Nec8cb6d3146841c89a9fac37e3ac40c3 schema:name nlm_unique_id
136 schema:value 8406521
137 rdf:type schema:PropertyValue
138 Nf9e8e061759e42dcaee5202b25a528d2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Mice
140 rdf:type schema:DefinedTerm
141 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
142 schema:name Medical and Health Sciences
143 rdf:type schema:DefinedTerm
144 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
145 schema:name Oncology and Carcinogenesis
146 rdf:type schema:DefinedTerm
147 sg:journal.1094644 schema:issn 0724-8741
148 1573-904X
149 schema:name Pharmaceutical Research
150 rdf:type schema:Periodical
151 sg:person.010236660502.77 schema:affiliation https://www.grid.ac/institutes/grid.14925.3b
152 schema:familyName Bertrand
153 schema:givenName Jean-Rémy
154 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010236660502.77
155 rdf:type schema:Person
156 sg:person.01037610656.22 schema:affiliation https://www.grid.ac/institutes/grid.14925.3b
157 schema:familyName Malvy
158 schema:givenName Claude
159 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01037610656.22
160 rdf:type schema:Person
161 sg:person.01146450602.87 schema:affiliation https://www.grid.ac/institutes/grid.14925.3b
162 schema:familyName Fattal
163 schema:givenName Elias
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01146450602.87
165 rdf:type schema:Person
166 sg:person.01266265435.77 schema:affiliation N544fe22ffad843a8b510a8431cde39c3
167 schema:familyName Lambert
168 schema:givenName Gregory
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01266265435.77
170 rdf:type schema:Person
171 sg:person.01340771606.27 schema:affiliation https://www.grid.ac/institutes/grid.432920.e
172 schema:familyName Maksimenko
173 schema:givenName Andrei
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340771606.27
175 rdf:type schema:Person
176 sg:person.0760312615.72 schema:affiliation N5f3a7c8e6439498f843c7abc0eb97ddd
177 schema:familyName Couvreur
178 schema:givenName Patrick
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0760312615.72
180 rdf:type schema:Person
181 sg:person.0761332540.51 schema:affiliation https://www.grid.ac/institutes/grid.5842.b
182 schema:familyName Maccario
183 schema:givenName Jean
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0761332540.51
185 rdf:type schema:Person
186 sg:pub.10.1023/a:1007582332491 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032461777
187 https://doi.org/10.1023/a:1007582332491
188 rdf:type schema:CreativeWork
189 sg:pub.10.1023/a:1015871809313 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035402570
190 https://doi.org/10.1023/a:1015871809313
191 rdf:type schema:CreativeWork
192 https://doi.org/10.1006/bbrc.2000.3963 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017328614
193 rdf:type schema:CreativeWork
194 https://doi.org/10.1080/07328319908044865 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041217538
195 rdf:type schema:CreativeWork
196 https://doi.org/10.1172/jci119152 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014854312
197 rdf:type schema:CreativeWork
198 https://www.grid.ac/institutes/grid.14925.3b schema:alternateName Institut Gustave Roussy
199 schema:name Institut Gustave Roussy, CNRS UMR 1582, 39 rue Camille Desmoulins, 94805, Villejuif cedex, France
200 rdf:type schema:Organization
201 https://www.grid.ac/institutes/grid.432920.e schema:alternateName Onxeo (France)
202 schema:name BioAlliance Pharma, 59, Boulevard du Général Martial Valin, 75015, Paris, France
203 Institut Gustave Roussy, CNRS UMR 1582, 39 rue Camille Desmoulins, 94805, Villejuif cedex, France
204 rdf:type schema:Organization
205 https://www.grid.ac/institutes/grid.5842.b schema:alternateName University of Paris-Sud
206 schema:name INSERM, Université Paris-Sud, 94805, Villejuif, France
207 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...